New hope for slowing black lung disease
NCT ID NCT05288179
Summary
This study is testing whether pirfenidone capsules can help slow the progression of lung scarring in people with pneumoconiosis, a serious lung disease often caused by inhaling dust at work. The trial will involve 272 patients who will take either the drug or a placebo for 52 weeks to see if it helps preserve their lung function. The main goal is to confirm if the treatment is effective and safe for managing this chronic condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCONIOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing China-Japan Friendship Hospital
RECRUITINGBeijing, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.